Direct Endoscopic Necrosectomy Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

The global direct endoscopic necrosectomy market is estimated to grow from US$ 262.2 Mn in 2026 to US$ 494.9 Mn by 2033. The market is projected to record a CAGR of 9.5% during the forecast period from 2026 to 2033.

The direct endoscopic necrosectomy market is growing steadily, fueled by increasing demand for advanced imaging in oncology, drug discovery, and translational research. North America leads, supported by strong research funding and infrastructure. At the same time, Asia-Pacific is experiencing rapid growth driven by expanding research facilities, healthcare investments, and rising adoption of hybrid imaging technologies, thereby enhancing procedural efficiency and outcomes.

• Dominant Segment: Abdominal Scan is the leading diagnostic method, with a 59.3% share in 2025, in the direct endoscopic necrosectomy market, valued for its non-invasive detection of necrotic tissue, high-resolution imaging, and its ability to guide procedural planning. It enables accurate assessment of the extent of necrosis, supports real-time decision-making for intervention, and is widely adopted in hospitals, specialty clinics, and research facilities that perform minimally invasive necrosectomy.
• Dominant Region: North America leads the market with the largest share, supported by strong research funding, advanced healthcare infrastructure, and high adoption of minimally invasive procedures. Asia-Pacific is the fastest-growing region, driven by expanding healthcare facilities, rising adoption of advanced endoscopic technologies, and increasing clinical awareness of direct endoscopic necrosectomy.
• Market Drivers: Market growth is fueled by the increasing prevalence of pancreatitis and necrotizing conditions, rising demand for minimally invasive necrosectomy procedures, growth in hospital and specialty clinic infrastructure, and adoption of advanced imaging-guided endoscopic systems.
• Market Opportunity: Key opportunities include development of AI-enabled endoscopic systems, integration with advanced imaging technologies, expansion into emerging healthcare markets, increased collaboration with research institutions and CROs, and broader applications in translational and interventional gastroenterology.

Driver – Rising Prevalence of Necrotizing Pancreatitis

The prevalence of severe pancreatitis, particularly necrotizing pancreatitis, is a significant driver for the direct endoscopic necrosectomy market. Acute pancreatitis affects tens of millions globally, with estimated incidence rates of around 20–40 per 100,000 people per year in high-income countries. income regions and increasing overall cases worldwide. Approximately 10–20% of acute pancreatitis cases progress to necrotizing pancreatitis, a condition where pancreatic tissue undergoes irreversible necrosis. Patients with necrotizing pancreatitis face substantially higher morbidity and mortality (20–45% in complicated cases) compared with non-necrotizing forms, increasing the need for effective interventions such as direct endoscopic necrosectomy.

The growing burden of acute and necrotizing pancreatitis is expanding procedural demand for therapeutic interventions. Globally, acute pancreatitis incidence has risen to nearly 2.8 million new cases annually, with moderate to severe forms causing significant hospitalizations and complications. Severe necrotizing pancreatitis, occurring in about one-fifth of acute cases, is associated with serious complications, including organ failure and infected necrosis, often necessitating interventional debridement. This clinical burden drives adoption of minimally invasive procedures like direct endoscopic necrosectomy, particularly in regions with advanced healthcare infrastructure, aligning market expansion with the epidemiological trend of increasing severe pancreatic disease.

Restraints – Complexity of Procedures

Direct Endoscopic Necrosectomy (DEN) is technically demanding, which contributes to its restraint as a market driver despite its clinical benefits. The procedure involves navigating a flexible endoscope through pancreatic fluid collections and removing necrotic debris, often requiring multiple sessions per patient (median of ~6 procedures) to achieve complete debridement, reflecting procedural complexity and variability. DEN’s complication rates reported in larger patient series range roughly from 14% to 36%, including bleeding, perforation, and fistula formation. Such adverse events demand high-endoscopic skill and multidisciplinary coordination, deterring broader adoption in centers lacking specialized gastroenterology expertise or standardized protocols.

Evidence underscores the complexity of DEN as a barrier to wider adoption, despite it being less invasive than traditional surgery. Studies show DEN’s overall complication rate can reach up to ~36%, with bleeding occurring in about 18% of patients and perforations in approximately 4%, reflecting procedural challenges. The need for multiple sessions increases hospital stay duration and resource utilization, placing pressure on clinician availability and facility throughput. These factors not only heighten procedural risk but also improve training requirements and operational costs, thereby constraining expansion in centers with limited therapeutic endoscopy experience and hindering faster market growth of DEN.

Opportunity – Integration with Advanced Imaging Modalities

Integration of advanced imaging modalities with Direct Endoscopic Necrosectomy (DEN) represents a major opportunity to improve procedural precision and outcomes. Techniques such as contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) provide detailed cross-sectional views and high soft-tissue contrast, significantly aiding in delineating pancreatic anatomy and necrosis extent before intervention. For example, CT accuracy in pancreatic evaluation is reported at approximately 83.3%, whereas MRI reaches 89.1%, thereby enhancing diagnostic confidence. Combining these imaging data with endoscopic planning allows clinicians to target necrotic collections better and optimize debridement strategies, ultimately improving clinical decision-making and reducing complication risks.

Advanced imaging integration also supports real-time procedural guidance and risk mitigation in complex endoscopic interventions. Endoscopic ultrasound (EUS) alone demonstrates diagnostic accuracy of up to 93.7% when enhanced with contrast and elastography, underscoring how imaging advancements improve lesion characterization. Such precision is critical in selecting appropriate intervention timing and minimizing invasive debridement sessions. Moreover, advanced imaging modalities like narrow-band imaging and AI-based optical enhancement consistently improve diagnostic yield and reduce procedural variability. These improvements encourage broader adoption of DEN by increasing clinician confidence and procedural efficacy, thereby expanding the market in centers equipped with modern imaging systems and trained multidisciplinary teams.

By Diagnosis, Abdominal Scan Dominates the Direct Endoscopic Necrosectomy Market

Abdominal Scan dominates with 59.3% share of the global market in 2025, because they provide highly reliable, non?invasive visualization of pancreatic necrosis and complications. CT is the imaging modality of choice for evaluating the extent and severity of acute and necrotizing pancreatitis in clinical practice, with reported diagnostic accuracy of approximately 89.7% compared with surgical findings, indicating strong reliability in identifying necrotic tissue. Additionally, CT sensitivity for detecting pancreatic necrosis exceeds 90% in many protocols and demonstrates excellent specificity in extensive necrosis, making it superior to other modalities for procedural planning. This high diagnostic performance enables clinicians to assess necrosis location, fluid collections, and severity, guiding endoscopic intervention timing and strategy more effectively than urine tests or biopsies, which lack comparable anatomical detail or broad clinical utility.

By Application, Pancreatitis dominates, driven by high cancer incidence and extensive preclinical imaging needs

Pancreatitis dominates the By Application segment of the direct endoscopic necrosectomy market because it is a highly prevalent condition that frequently leads to complications requiring intervention. Acute pancreatitis is one of the most common gastrointestinal disorders globally, with an estimated 33.7 cases per 100,000 person-years and accounting for over 275,000 hospital admissions annually in the United States alone. Severe forms of acute pancreatitis can progress to pancreatic necrosis in approximately 10–20% of patients, significantly increasing morbidity and need for procedural treatment. Moreover, necrotizing pancreatitis carries mortality rates of up to 20–45% in complicated cases and often results in walled-off necrosis or infected collections that necessitate direct endoscopic necrosectomy for effective debridement and patient management.

North America Direct Endoscopic Necrosectomy Market Trends

North America dominates the direct endoscopic necrosectomy market with a 39.6% share in 2025, driven by advanced healthcare infrastructure, strong procedural adoption, and a high disease burden. In the United States, acute pancreatitis an indication frequently requiring interventions such as endoscopic necrosectomy accounts for more than 275,000 hospital admissions annually, driving clinical demand for advanced diagnostic and therapeutic endoscopic procedures.?Contrast?enhanced imaging and minimally invasive endoscopic techniques are widely available and integrated into standard care pathways in North American hospitals, supported by leading medical centers and well?established referral networks.?Additionally, North America historically holds the largest share of endoscopic procedures globally due to high healthcare spending, favorable reimbursement policies, and broad access to innovative technologies, which collectively reinforce its leadership in the DEN market.

Europe Direct Endoscopic Necrosectomy Market Trends

Europe is an important region in the direct endoscopic necrosectomy market due to its substantial burden of pancreatitis and well-developed endoscopic practice infrastructure. Across Europe, incidence rates of acute pancreatitis vary widely from as low as 4.6 to as high as 100 cases per 100,000 population in different countries indicating significant clinical demand for interventions associated with complications such as necrosis.?The region’s strong healthcare systems, particularly in Western Europe, support widespread adoption of advanced endoscopic diagnostics and therapeutic procedures, with increasing volumes of pancreaticobiliary and interventional endoscopy reported historically. National clinical guidelines and investment in interventional endoscopy training further strengthen Europe’s role, helping maintain high procedural standards and broader access to minimally invasive necrosectomy options.

Asia-Pacific Direct Endoscopic Necrosectomy Market Trends

Asia Pacific is the fastest-growing region in the direct endoscopic necrosectomy marketdue to increasing prevalence of pancreatitis and related complications, expanding healthcare infrastructure, and rising adoption of minimally invasive procedures. Acute pancreatitis incidence in countries like China and India is reported at approximately 33–40 cases per 100,000 population per year, with severe necrotizing forms affecting 10–20% of patients. Government initiatives to improve hospital facilities, expand gastroenterology training programs, and install advanced imaging and endoscopic equipment are accelerating access. Growing awareness among clinicians and patients of the benefits of endoscopic necrosectomy over surgical interventions further drives market adoption across the region.

Leading imaging applications in the direct endoscopic necrosectomy market focus on precise pancreatic necrosis assessment, procedural planning, and minimally invasive intervention. High-resolution abdominal scans and imaging guidance improve visualization of necrotic tissue, enhance procedural accuracy, and support efficient clinical workflows, reducing complications. These capabilities drive adoption across hospitals and specialty centers, fueling market growth and expanding clinical acceptance globally.

• In April 2025, Medtronic announced a distribution agreement with Dragonfly™ Endoscopy, expanding its offerings in pancreaticobiliary endoscopy. Through this partnership, Medtronic became the authorized distributor of Dragonfly™ Endoscopy’s products, aiming to enhance clinical access to advanced endoscopic tools for diagnosing and treating pancreatic and biliary conditions. The collaboration strengthened Medtronic’s portfolio in minimally invasive gastrointestinal interventions.
• In March 2024, Cook Medical and Bentley entered a distribution agreement for the BeBack® Catheter in the United States. Under the agreement, Cook Medical became the official distributor of Bentley’s BeBack® Catheter, expanding its portfolio in interventional devices. The partnership aimed to enhance market reach and provide U.S. healthcare providers with improved access to the catheter for advanced vascular procedures.